+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast to 2030- Product Image
Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast to 2030- Product Image
Sale

Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666371
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The viral vectors market is experiencing transformative growth, fueled by breakthroughs in gene and cell therapy, vaccine development, and emerging applications in molecular medicine. As a pivotal sector enabling next-generation therapies, decision-makers need deep, actionable insights to navigate increasing complexity and capitalize on new opportunities.

Market Snapshot: Viral Vectors Market Trends and Performance

The Viral Vectors Market grew from USD 1.88 billion in 2024 to USD 2.16 billion in 2025. It is expected to continue growing at a CAGR of 14.19%, reaching USD 4.19 billion by 2030.

Scope & Segmentation

  • Vector Types: Adeno-associated virus (including AAV2, AAV8, AAV9), adenovirus, lentivirus, and retrovirus are all central to therapeutic development pipelines and research.
  • Applications: Cell therapy (CAR T, dendritic, TCR T), gene therapy (ex vivo, in vivo), research (basic, preclinical), and vaccines (prophylactic and therapeutic) are mainstay uses driving platform demand.
  • Therapeutic Areas: Key areas include oncology, neurological disorders, cardiovascular disorders, infectious diseases, and rare monogenic conditions.
  • End Users: Biopharma companies, hospitals and clinics, and research institutes are primary adopters at different stages of clinical and commercial scale-up.
  • Production Stages: Coverage spans upstream processing (cell expansion, harvesting, transfection) and downstream steps (filtration, formulation, purification via chromatography and ultracentrifugation).
  • Production Scale: Clinical (Phase I, II, III) and commercial full-scale manufacturing environments define throughput and capability requirements.
  • Regional Coverage: The Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Middle East centers, and more), and Asia-Pacific (China, India, Japan, South Korea, Southeast Asia) are analyzed for their specific dynamics and market drivers.
  • Companies Covered: Analysis highlights Thermo Fisher Scientific, Lonza Group, Merck KGaA, Catalent, WuXi AppTec, Novasep, Oxford BioMedica, AGC Biologics, Cobra Biologics, and Viralgen, among others.

Key Takeaways for Senior Decision-Makers

  • Advancements in vector engineering and manufacturing are rapidly enhancing therapeutic reach and R&D capabilities, making flexibility in process design a priority.
  • Strategic partnerships with contract manufacturers, academic institutes, and CROs are accelerating innovation cycles and mitigating development risk as the sector matures.
  • Integrated, modular manufacturing assets and digital process controls are emerging as critical differentiators, enabling faster transitions from clinical to commercial production.
  • Regulatory frameworks are increasingly focused on adaptive trial designs, real-world evidence, and robust quality standards, influencing how new therapies are evaluated and brought to market.
  • Supply chain agility and regional production diversification support resilience against policy changes, ensuring continuity amid rising complexity and demand variability.
  • Emergence of next-generation platforms targeting complex indications is driving a wave of consolidation and specialization among leading viral vector solution providers.

Tariff Impact on the Viral Vectors Value Chain

Recent U.S. tariffs on critical raw materials and single-use components are intensifying cost pressures for manufacturers and biotech companies alike. These policy developments have prompted a renewed focus on sourcing strategies, nearshoring, and domestic manufacturing capacity. While established players leverage their positions to secure access and manage pricing volatility, market entrants face higher barriers. Modular facility investments and collaborative frameworks with regulatory agencies are helping firms navigate these shifts, while supply chain adaptability remains vital for sustained competitive advantage.

Methodology & Data Sources

This report combines primary interviews with senior R&D, manufacturing, and regulatory experts with secondary research sourced from journals, patents, and industry white papers. Quantitative datasets are drawn from proprietary databases and trade statistics, cross-validated through expert panels and scenario modeling. Rigorous quality assurance processes underpin every phase of analysis to ensure reliable, actionable insights.

Why This Report Matters for Market Leaders

  • Provides an end-to-end view of the viral vectors market landscape, empowering organizations to align investments with evolving therapeutic, technological, and regulatory trends.
  • Delivers concrete competitive intelligence, supporting strategic decisions on manufacturing, regional expansion, and partnership formation to unlock new growth pathways.

Conclusion

The viral vectors sector is transforming with rapid advances, intensifying competition, and shifting global policies. This report delivers a comprehensive framework for informed, strategic leadership and sustainable market growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Viral Vectors Market, by Vector Type
8.1. Introduction
8.2. Adeno Associated Virus
8.2.1. AAV2
8.2.2. AAV8
8.2.3. AAV9
8.3. Adenovirus
8.4. Lentivirus
8.5. Retrovirus
9. Viral Vectors Market, by Application
9.1. Introduction
9.2. Cell Therapy
9.2.1. Car T
9.2.2. Dendritic
9.2.3. TCR T
9.3. Gene Therapy
9.3.1. Ex Vivo
9.3.2. In Vivo
9.4. Research
9.4.1. Basic Research
9.4.2. Preclinical Research
9.5. Vaccine
9.5.1. Prophylactic
9.5.2. Therapeutic
10. Viral Vectors Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular Disorders
10.2.1. Coronary
10.2.2. Peripheral Vascular
10.3. Infectious Disease
10.3.1. Bacterial
10.3.2. Viral
10.4. Neurological Disorders
10.4.1. Neurodegenerative
10.4.2. Neurodevelopmental
10.5. Oncology
10.5.1. Hematological
10.5.2. Solid Tumor
10.6. Rare Diseases
10.6.1. Monogenic
11. Viral Vectors Market, by End User
11.1. Introduction
11.2. Biopharma Companies
11.3. Hospitals And Clinics
11.4. Research Institutes
12. Viral Vectors Market, by Production Stage
12.1. Introduction
12.2. Downstream
12.2.1. Filtration
12.2.2. Formulation
12.2.3. Purification
12.2.3.1. Chromatography
12.2.3.2. Ultracentrifugation
12.3. Upstream
12.3.1. Cell Expansion
12.3.2. Harvesting
12.3.3. Transfection
13. Viral Vectors Market, by Production Scale
13.1. Introduction
13.2. Clinical
13.2.1. Phase I
13.2.2. Phase II
13.2.3. Phase III
13.3. Commercial
13.3.1. Full Scale
14. Americas Viral Vectors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Viral Vectors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Viral Vectors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. Lonza Group AG
17.3.3. Merck KGaA
17.3.4. Catalent Inc.
17.3.5. WuXi AppTec Co., Ltd.
17.3.6. Novasep Holding SAS
17.3.7. Oxford BioMedica plc
17.3.8. AGC Biologics Inc.
17.3.9. Cobra Biologics Ltd.
17.3.10. Viralgen S.L.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. VIRAL VECTORS MARKET MULTI-CURRENCY
FIGURE 2. VIRAL VECTORS MARKET MULTI-LANGUAGE
FIGURE 3. VIRAL VECTORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY FULL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 124. CANADA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 125. CANADA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 126. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. CANADA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 128. CANADA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 129. CANADA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 130. CANADA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 131. CANADA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. CANADA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. CANADA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 134. CANADA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. CANADA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CANADA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 137. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 139. CANADA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 140. CANADA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 141. CANADA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 142. CANADA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 143. CANADA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 144. CANADA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 145. MEXICO VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. MEXICO VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 149. MEXICO VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 150. MEXICO VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 151. MEXICO VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. MEXICO VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 155. MEXICO VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 157. MEXICO VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 161. MEXICO VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 162. MEXICO VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 163. MEXICO VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 164. MEXICO VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 165. MEXICO VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 251. GERMANY VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 252. GERMANY VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 253. GERMANY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. GERMANY VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 255. GERMANY VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 256. GERMANY VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 257. GERMANY VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 258. GERMANY VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 259. GERMANY VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 260. GERMANY VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 261. GERMANY VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. GERMANY VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 264. GERMANY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. GERMANY VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 266. GERMANY VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 267. GERMANY VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 268. GERMANY VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 269. GERMANY VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 270. GERMANY VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 271. GERMANY VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 272. FRANCE VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 273. FRANCE VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 274. FRANCE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. FRANCE VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 276. FRANCE VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 277. FRANCE VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 278. FRANCE VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 279. FRANCE VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 280. FRANCE VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 281. FRANCE VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 282. FRANCE VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 284. FRANCE VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 285. FRANCE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. FRANCE VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 287. FRANCE VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 288. FRANCE VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 289. FRANCE VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 290. FRANCE VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 291. FRANCE VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 292. FRANCE VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 293. RUSSIA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 294. RUSSIA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 308. RUSSIA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 309. RUSSIA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 310. RUSSIA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 311. RUSSIA VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 314. ITALY VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 315. ITALY VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 316. ITALY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. ITALY VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 318. ITALY VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 319. ITALY VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 320. ITALY VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 321. ITALY VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 322. ITALY VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 323. ITALY VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 324. ITALY VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 325. ITALY VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 326. ITALY VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 327. ITALY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. ITALY VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 329. ITALY VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 330. ITALY VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 331. ITALY VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 332. ITALY VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 333. ITALY VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 334. ITALY VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 335. SPAIN VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 336. SPAIN VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 337. SPAIN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. SPAIN VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 339. SPAIN VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 340. SPAIN VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 341. SPAIN VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 342. SPAIN VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 343. SPAIN VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
TABLE 344. SPAIN VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 345. SPAIN VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 346. SPAIN VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 347. SPAIN VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 348. SPAIN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. SPAIN VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2030 (USD MILLION)
TABLE 350. SPAIN VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
TABLE 351. SPAIN VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2030 (USD MILLION)
TABLE 352. SPAIN VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
TABLE 353. SPAIN VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 354. SPAIN VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2030 (USD MILLION)
TABLE 355. SPAIN VIRAL VECTORS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 356. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2030 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 361. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 362. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 363.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Viral Vectors market report include:
  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Merck KGaA
  • Catalent Inc.
  • WuXi AppTec Co., Ltd.
  • Novasep Holding SAS
  • Oxford BioMedica plc
  • AGC Biologics Inc.
  • Cobra Biologics Ltd.
  • Viralgen S.L.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.19 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast to 2030 - Product Image

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region - Product Image

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region

  • Report
  • 768 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market by Service Type, Product Type, Application, Technology Platform, Scale, End User - Global Forecast to 2030 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market by Service Type, Product Type, Application, Technology Platform, Scale, End User - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Viral Vector Manufacturing - Global Strategic Business Report - Product Image

Viral Vector Manufacturing - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From
Viral Vector Production (Research-Use) - Global Strategic Business Report - Product Image

Viral Vector Production (Research-Use) - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From

About the Market

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases. Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field. The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.